Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$40.56M+57.70%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark Van Oene
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 485
- Beta
- 2.20
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -4.97
Financials
Revenue
$40.56M+57.7%Net Income
$-37.85MEBITDA
$-35.52MFree Cash Flow
$-38.59MEPS (diluted)
$-0.12Shares Outstanding (diluted)
311.25M+234.8%Operating Expenses
$49.64MCash & Debt
$199.42MRevenue by Segment (annual)
$295.76MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $160.00M | $-546.38M | $-1.82 |
| 2024 | $154.01M | $-309.85M | $-1.13 |
| 2023 | $200.52M | $-306.74M | $-1.21 |
| 2022 | $128.30M | $-314.25M | $-1.40 |
| 2021 | $130.51M | $-181.22M | $-0.89 |
| 2020 | $78.89M | $29.40M | $0.18 |
| 2019 | $90.89M | $-84.13M | $-0.51 |
| 2018 | $78.63M | $-102.56M | $-0.76 |
| 2017 | $93.47M | $-92.19M | $-0.87 |
| 2016 | $90.71M | $-74.38M | $-0.83 |
| 2015 | $92.78M | $-31.70M | $-0.42 |
| 2014 | $60.59M | $-66.16M | $-0.94 |
| 2013 | $28.18M | $-79.29M | $-1.26 |
| 2012 | $25.98M | $-94.47M | $-1.69 |
Valuation
PACBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
43+44.44%Social Signal Score
Mentions (21)
- Newsseekingalpha.com·17d ago·Neutral
Pacific Biosciences Q3: Another Revenue Guidance Cut Pacific Biosciences reported mixed Q3 results, with revenues beating reduced estimates but gross margins falling. Despite continually declining street revenue estimates, management was disappointed with guidance as it trimmed its 2026 sales forecast. The company continues to burn large amounts of cash, weakening the balance sheet considerably over time.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Pacific Biosciences of California, Inc. (PACB) Q3 2026 Earnings Call Transcript Pacific Biosciences of California, Inc. (PACB) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·18d ago·Neutral
What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call Pacific Biosciences of California NASDAQ: PACB reported 6% revenue growth for the third quarter of 2026 as customers adopted its SPRQ-Nx sequencing chemistry, though consumables revenue declined from a year earlier and academic funding constraints continued to weigh on instrument purchases in the Americas.
View source ↗ - Newszacks.com·24d ago·Neutral
Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts In the latest trading session, Pacific Biosciences of California (PACB) closed at $2.9, marking a +2.47% move from the previous day.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
PacBio to Participate in Upcoming Investor Conferences MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
View source ↗ - Newszacks.com·26d ago·Neutral
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin pressures persist.
View source ↗ - Newszacks.com·31d ago·Neutral
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.06, representing a -3.74% change from its previous close.
View source ↗ - Newsglobenewswire.com·34d ago·Positive
PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows
View source ↗ - Newszacks.com·39d ago·Neutral
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.99, indicating a -2.93% shift from the previous trading day.
View source ↗ - Newszacks.com·40d ago·Negative
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics PACB partners with TychoBio to harness AI and long-read RNA sequencing for rare disease therapies, aiming to improve drug efficacy and safety through advanced data models.
View source ↗ - Newszacks.com·45d ago·Neutral
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a -15.44% change from its previous close.
View source ↗ - Newsglobenewswire.com·47d ago·Negative
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models
View source ↗ - Newszacks.com·51d ago·Neutral
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts Pacific Biosciences of California (PACB) concluded the recent trading session at $2.54, signifying a +1.2% move from its prior day's close.
View source ↗ - Newszacks.com·58d ago·Positive
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.
View source ↗ - Newsmarketbeat.com·63d ago·Neutral
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push Pacific Biosciences of California NASDAQ: PACB is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve sequencing economics, Chief Executive Officer Mark Van Oene said during a Morgan Stanley discussion.
View source ↗ - Newszacks.com·66d ago·Neutral
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.
View source ↗ - Newsseekingalpha.com·67d ago·Positive
Pacific Biosciences of California, Inc. (PACB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Pacific Biosciences of California, Inc. (PACB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·73d ago·Neutral
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, marking a -1.55% move from the prior day.
View source ↗ - Newszacks.com·79d ago·Neutral
Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue? Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·81d ago·Negative
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.
View source ↗ - Newsmarketbeat.com·98d ago·Neutral
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity Pacific Biosciences of California NASDAQ: PACB reported second-quarter revenue of $39 million, including $20 million in consumables revenue, $13 million in instrument revenue and $6 million in services revenue, CFO Jim Gibson said during the Canaccord Genuity Growth Conference.
View source ↗
Earnings
Tue, Feb 9(in 3 months)
Consensus estimate $-0.13 per share
Typical surprise +25.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.11 vs $-0.13beat
- Wed, Aug 5$-0.14 vs $-0.14beat
- Thu, May 7$-0.03 vs $-0.17beat
- Thu, Feb 12$-0.12 vs $-0.19beat
- Wed, Nov 5$-0.12 vs $-0.16beat
- Thu, Aug 7$-0.13 vs $-0.18beat
Estimates and results for PACB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PACB officers and directors.
- Bought
- $176k
- Sold
- $4.7m
1 trade
31 trades
- Ordonez Kathysold
- Gibson James R Iisold
- Van Oene Marksold
- Gibson James R Iisold
- Henry Christian Osold
- Van Oene Marksold
- Farmer Michelesold
- Van Oene Marksold
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PACB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
